SCHEMBL13128200

SCHEMBL13128200

CON=C1CCN(c2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.44
CYP3A4 P08684 2/20 0.44
MAPK1 P28482 2/20 0.44
ALOX15 P16050 1/20 0.44
CHRNB2 P17787 1/20 0.44
NFKB1 P19838 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 5/20 0.44
ALDH1A1 P00352 4/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
APOBEC3A P31941 1/20 0.43
PMP22 Q01453 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646814 0.82 MAPT (0.50) CYP3A4MAPK1ALOX15HSD17B10MAPT
SCHEMBL8911501 0.75 CHRNA7 (0.48) CHRNA7CYP3A4MAPK1ALOX15CHRNB2
SCHEMBL942093 0.75 GAA (0.51) CHRNA7CYP3A4MAPK1ALOX15CHRNB2
SCHEMBL11463836 0.74 SIGMAR1 (0.55) MAPK1MAPTALDH1A1MEN1KMT2A
SCHEMBL8005398 0.73 MAPT (0.43) MAPK1ALOX15HSD17B10MAPTALDH1A1
Hydrochloric Acid SCHEMBL28776375 0.71 CYP3A4 (0.35) CHRNA7CYP3A4MAPK1ALOX15CHRNB2
SCHEMBL385012 0.70
SCHEMBL164538 0.70 LMNA (0.67) CHRNA7CYP3A4MAPK1ALOX15CHRNB2
SCHEMBL576814 0.70 LMNA (0.67) CHRNA7CYP3A4MAPK1ALOX15CHRNB2
SCHEMBL576454 0.70 LMNA (0.67) CHRNA7CYP3A4MAPK1ALOX15CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods IL4, IL2, TH CHRNA7 2363/4885CYP3A4 119/4885MAPK1 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.